MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for...

Full description

Bibliographic Details
Main Authors: Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Acta Pharmaceutica Sinica B
Subjects:
MET inhibitor
Tepotinib
Multidrug resistance
ABCG2 transporter
Reversal agent
Combination treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383521004901

Internet

http://www.sciencedirect.com/science/article/pii/S2211383521004901

Similar Items